ReviewMedicine2025
Clinicopathological observation of adult malignant ectodermal mesenchymoma: A case report and literature review.
Review in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
rationaleMalignant ectomesenchymoma (MEM) is a relatively rare soft tissue tumor, which predominantly occurs in infants or children under 15 years of age. The classic sites of occurrence are the pelvic perineal region and genitourinary system. Compared to pediatric cases, adult cases exhibit certain differences in clinicopathological features and are more prone to misdiagnosis. A thorough comprehension of their clinicopathologic features is crucial for precise diagnosis and effective management. PATIENT CONCERNS: A 23-year-old male had a lesion located on the right side of his head and face, and the disease course lasted 13 months. A retrospective analysis was conducted on the clinicopathological data, histopathological features, immunophenotype, and molecular pathological changes. DIAGNOSES: The tumor was composed of embryonal rhabdomyosarcoma and undifferentiated neuroectodermal components. Immunohistochemistry showed positivity for rhabdomyosarcoma markers such as Desmin, MyoD1, and Myogenin in the rhabdomyosarcomatous component and positivity for neuroectodermal markers, including synaptophysin and chromogranin A in the neuroectodermal component. No specific molecular alterations were detected in genetic testing.
interventionsThis is a case of initial misdiagnosis, multimodal comprehensive treatment combining surgery with chemotherapy was the primary therapeutic approach, However, poor clinical outcomes were observed. OUTCOMES: Despite aggressive treatments, the patient died of the disease after 1 year of follow-up. LESSONS: Adult MEM is a biphenotypic sarcoma composed of rhabdomyosarcoma and neuroectodermal tissues. Morphological and immunohistochemical interpretation is crucial for diagnosis. treatment approaches and prognosis are correlated with the completeness of tumor resection and the differentiation degree of both components.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.